KR102410696B1 - 암 치료법의 조합 - Google Patents

암 치료법의 조합 Download PDF

Info

Publication number
KR102410696B1
KR102410696B1 KR1020167030676A KR20167030676A KR102410696B1 KR 102410696 B1 KR102410696 B1 KR 102410696B1 KR 1020167030676 A KR1020167030676 A KR 1020167030676A KR 20167030676 A KR20167030676 A KR 20167030676A KR 102410696 B1 KR102410696 B1 KR 102410696B1
Authority
KR
South Korea
Prior art keywords
compound
composition
her2
her2 inhibitor
breast cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020167030676A
Other languages
English (en)
Korean (ko)
Other versions
KR20160133005A (ko
Inventor
베이어드 알 허크
에릭 윌커
안드레아스 마흘
레미지우시 칼레타
Original Assignee
메르크 파텐트 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 메르크 파텐트 게엠베하 filed Critical 메르크 파텐트 게엠베하
Publication of KR20160133005A publication Critical patent/KR20160133005A/ko
Application granted granted Critical
Publication of KR102410696B1 publication Critical patent/KR102410696B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020167030676A 2014-04-03 2015-03-09 암 치료법의 조합 Active KR102410696B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461974765P 2014-04-03 2014-04-03
US61/974,765 2014-04-03
PCT/EP2015/000525 WO2015149909A1 (en) 2014-04-03 2015-03-09 Combinations of cancer therapeutics

Publications (2)

Publication Number Publication Date
KR20160133005A KR20160133005A (ko) 2016-11-21
KR102410696B1 true KR102410696B1 (ko) 2022-06-17

Family

ID=52692591

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020167030676A Active KR102410696B1 (ko) 2014-04-03 2015-03-09 암 치료법의 조합

Country Status (15)

Country Link
US (1) US9980966B2 (OSRAM)
EP (1) EP3125935B1 (OSRAM)
JP (1) JP6629753B2 (OSRAM)
KR (1) KR102410696B1 (OSRAM)
CN (1) CN106456752B (OSRAM)
AR (1) AR099931A1 (OSRAM)
AU (1) AU2015240094B2 (OSRAM)
CA (1) CA2944573C (OSRAM)
ES (1) ES2768900T3 (OSRAM)
IL (1) IL248126A0 (OSRAM)
MX (1) MX370540B (OSRAM)
NZ (1) NZ725361A (OSRAM)
RU (1) RU2733401C2 (OSRAM)
SG (1) SG11201608189WA (OSRAM)
WO (1) WO2015149909A1 (OSRAM)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022101459A1 (en) * 2020-11-16 2022-05-19 Merck Patent Gmbh Kinase inhibitor combinations for cancer treatment
WO2025168601A1 (en) * 2024-02-05 2025-08-14 Evexta Bio Quinazoline carboxamide azetidine compounds for use in treating hormone dependent diseases

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200306819A (en) 2002-01-25 2003-12-01 Vertex Pharma Indazole compounds useful as protein kinase inhibitors
WO2004092154A1 (en) 2003-04-03 2004-10-28 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases
US7189729B2 (en) 2003-09-30 2007-03-13 Irm Llc Methods and compositions as protein kinase inhibitors
WO2005039506A2 (en) 2003-10-24 2005-05-06 Exelixis, Inc. P70s6 kinase modulators and method of use
BRPI0416801A (pt) 2003-11-21 2007-01-09 Novartis Ag derivados de 1h-imidazoquinolina como inibidores de proteìna sinase
RU2006124421A (ru) 2003-12-09 2008-01-20 ПРАВИТЕЛЬСТВО СОЕДИНЕННЫХ ШТАТОВ АМЕРИКИ, ПРЕДСТАВЛЕННОЕ СЕКРЕТАРЕМ ДЕПАРТАМЕНТА ЗДРАВООХРАНЕНИЯ И СЛУЖБЫ ДЛЯ ЛЮДЕЙ, УС Национальный Институт здравоохранени , Ведомство по передаче технологий (US) Способ подавления ответной иммунной реакции или лечения пролиферативного нарушения
JP5213229B2 (ja) 2004-04-23 2013-06-19 エグゼリクシス， インコーポレイテッド キナーゼ調節因子および使用方法
ATE543821T1 (de) 2004-12-28 2012-02-15 Exelixis Inc Ä1h-pyrazoloä3,4-düpyrimidin-4-ylü-piperidin- oder piperazinverbindungen als serin-threonin- kinasemodulatoren (p70s6k, atk1 und atk2) zur behandlung von immunologischen, entzündlichen und proliferativen erkrankungen
GB0501999D0 (en) 2005-02-01 2005-03-09 Sentinel Oncology Ltd Pharmaceutical compounds
US20060188498A1 (en) * 2005-02-18 2006-08-24 Genentech, Inc. Methods of using death receptor agonists and EGFR inhibitors
WO2006136821A1 (en) 2005-06-22 2006-12-28 Astex Therapeutics Limited Pharmaceutical compounds
CN101300029A (zh) * 2005-11-04 2008-11-05 惠氏公司 mTOR抑制剂、赫赛汀和/或HKI-272的抗肿瘤组合
UA99284C2 (ru) 2007-05-11 2012-08-10 Елі Ліллі Енд Компані ИНГИБИТОРЫ р70 S6-КИНАЗЫ
UY31800A (es) 2008-05-05 2009-11-10 Smithkline Beckman Corp Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb
CA2751886C (en) 2009-02-11 2017-08-29 Merck Patent Gmbh Novel amino azaheterocyclic carboxamides
AU2011254557B2 (en) 2010-05-20 2015-09-03 Ablynx Nv Biological materials related to HER3
UA110113C2 (xx) 2010-07-29 2015-11-25 Біциклічні азагетероциклічні карбоксаміди
EP2643313B9 (en) * 2010-11-24 2017-02-22 Merck Patent GmbH Quinazoline carboxamide azetidines
SG10201900954SA (en) 2013-03-11 2019-02-27 Merck Patent Gmbh Heterocycles as Modulators of Kinase Activity

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Celina Garcia-Carcia, et al., Clinical Cancer Reserach, 2012, 18(9), 2603-2612. (2012.03.08.)*
공개특허공보 제10-2013-0130753호 (2013.12.02.)*

Also Published As

Publication number Publication date
US20170100402A1 (en) 2017-04-13
JP2017509683A (ja) 2017-04-06
AU2015240094B2 (en) 2020-07-30
RU2733401C2 (ru) 2020-10-01
KR20160133005A (ko) 2016-11-21
US9980966B2 (en) 2018-05-29
CN106456752B (zh) 2020-11-20
CN106456752A (zh) 2017-02-22
ES2768900T3 (es) 2020-06-24
AR099931A1 (es) 2016-08-31
WO2015149909A1 (en) 2015-10-08
JP6629753B2 (ja) 2020-01-15
EP3125935B1 (en) 2019-10-23
RU2016143153A (ru) 2018-05-04
IL248126A0 (en) 2016-11-30
AU2015240094A1 (en) 2016-11-17
NZ725361A (en) 2022-09-30
MX2016012825A (es) 2017-01-05
CA2944573C (en) 2022-10-25
BR112016020135A8 (pt) 2021-07-06
RU2016143153A3 (OSRAM) 2018-10-17
MX370540B (es) 2019-12-17
EP3125935A1 (en) 2017-02-08
SG11201608189WA (en) 2016-10-28
BR112016020135A2 (pt) 2017-08-15
CA2944573A1 (en) 2015-10-08

Similar Documents

Publication Publication Date Title
TR201901348T4 (tr) Metap-2 inhibitörleri olarak pirolidinon türevleri.
AU2013234767A1 (en) Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with other anti-tumor compounds
KR102410696B1 (ko) 암 치료법의 조합
US20240226104A1 (en) Pi3k inhibitors, nanoformulations, and uses thereof
CN109715164A (zh) 作为用于治疗脑癌之治疗剂的2-苯胺基嘧啶衍生物
US20230405118A1 (en) Stat-activated macrophages, compositions, and uses thereof
US11684672B2 (en) Combinations of copanlisib with anti-PD-1 antibody
BR112016020135B1 (pt) Mistura de compostos, seus usos, composição farmacêutica, e conjunto (kit)
JP2018502863A (ja) 白血病の治療のための４−（４−フルオロ−２−メトキシフェニル）−ｎ−｛３−［（ｓ−メチルスルホンイミドイル）メチル］フェニル｝−１，３，５−トリアジン−２−アミンの使用
US20240382495A1 (en) Combinations of copanlisib with anti-pd-1 antibody
US20230248695A1 (en) Combinations of cancer therapeutics
JP7791163B2 (ja) メチオニンアミノペプチダーゼ２阻害剤とｖｅｇｆｒ／ｖｅｇｆ阻害剤の組み合わせ（がん治療薬の組み合わせ）
US20240024324A1 (en) Kinase inhibitor combinations for cancer treatment
CN120712263A (zh) 瞬时受体电位香草素6抑制剂
HK40087859A (zh) Cdk4抑制剂的固体形式
WO2019079747A1 (en) INHIBITORS OF RET9 AND VEGFR2

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20161102

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200305

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20210908

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20220223

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20210908

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20220223

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20211105

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20200305

Comment text: Amendment to Specification, etc.

PX0701 Decision of registration after re-examination

Patent event date: 20220324

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20220315

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20220223

Comment text: Decision to Refuse Application

Patent event code: PX07011S01I

Patent event date: 20211105

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20200305

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20220615

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20220615

End annual number: 3

Start annual number: 1

PG1601 Publication of registration